Study Finds No Increased Risk of Neurodevelopmental Disorders from Paternal Valproate Use

A comprehensive international study of over 1.3 million children from two countries challenges earlier European safety warnings about valproate use in fathers. Researchers from National Taiwan University and the University of Oslo found that previous concerns about paternal valproate exposure and neurodevelopmental disorders weaken significantly when accounting for underlying parental conditions and other confounding factors. The findings suggest that the drug's underlying indication—rather than the medication itself—may explain earlier observed associations. This research provides important reassurance for patients and families considering valproate therapy, though medical consultation remains essential for individual treatment decisions.